Noradrenaline (Tartrate) (Sans Sulfites) Aguettant (Noradrenaline Tartrate)

Noradrenaline acts as an agonist at α1‑adrenergic receptors, causing peripheral blood‑vessel constriction, and at β1‑adrenergic receptors, increasing heart‑muscle contractility and rate. The combined effect elevates systemic vascular resistance and cardiac output, thereby raising arterial pressure.

The dose of noradrenaline is individualized and set by the prescribing clinician based on the patient’s hemodynamic status, target blood‑pressure goals, and response to therapy. Infusion rates are titrated in micrograms per kilogram per minute under continuous monitoring.

Safety data for noradrenaline in pregnancy and lactation are limited. It should only be used when clearly needed and when the potential benefit outweighs any possible risk to the fetus or infant, and under specialist supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Noradrenaline is often preferred for its balanced α1‑mediated vasoconstriction and modest β1 activity, providing reliable blood‑pressure support with fewer tachyarrhythmias than pure β‑agonists. Compared with dopamine, it has a lower risk of arrhythmias, while phenylephrine offers stronger α1 effect but lacks β1 support.

Noradrenaline must be stored at 2‑8 °C, protected from light, and kept in its original sealed container. Do not freeze or shake the solution. Before use, inspect for particulate matter and ensure aseptic technique during preparation and infusion.

Noradrenaline is administered intravenously, typically as a continuous infusion through a central or large peripheral vein. The infusion is prepared in a compatible diluent, and the rate is adjusted according to real‑time blood‑pressure and heart‑rate monitoring.

Serious risks include severe hypertension, cardiac arrhythmias, myocardial ischemia, and tissue necrosis if the drug extravasates. Continuous hemodynamic monitoring and immediate cessation of the infusion if extravasation is suspected are essential to mitigate these hazards.

Noradrenaline is contraindicated in patients with known hypersensitivity to the product, and it should be used with extreme caution—or avoided—in individuals with uncontrolled cardiac ischemia, severe arrhythmias, or peripheral vascular disease where excessive vasoconstriction could worsen tissue perfusion.